Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is among the 15 Best Small Cap Stocks to Buy According to Wall Street.

On February 4, 2026, Barclays raised its price target on CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $10 from $8 and maintained an Overweight rating as part of a fourth-quarter earnings preview for the biotechnology group.

Earlier, on January 20, 2026, Piper Sandler lifted its price target to $10 from $6.50 and kept an Overweight rating following initial Phase I data on varsetatug maseatecan. The firm noted that doses of 7.2–10 mg/kg delivered a 28% overall response rate, a 94% disease control rate, and a preliminary median progression-free survival of 5.8 months in third-line and later metastatic colorectal cancer. CytomX is expected to provide an update this quarter on approximately 100 mCRC patients across 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg q3W expansion cohorts, with Piper anticipating dose-dependent ORR and PFS benefits. Also on January 20, 2026, Guggenheim analyst Michael Schmidt initiated coverage with a Buy rating and a $10 price target, citing what he described as “extraordinary” antitumor activity from Varseta-M in a heavily pre-treated population. The firm’s $10 target reflects 30% odds of success in third-line and later colorectal cancer.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) develops conditionally activated biologics targeting the tumor microenvironment, including antibody-drug conjugates, T-cell engagers, immune modulators, and its PROBODY platform for oncology and preclinical applications.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street

Disclosure: None.